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MHCIBackground and purpose: Recently, we have shown that radiotherapy (RT) combined with the
immunocytokine L19-IL2 can induce long-lasting antitumour effects, dependent on ED-B expression
and inﬁltration of cytotoxic T cells. On the other hand, in certain tumours, IL2 treatment can trigger a
natural killer cell (NK) immune response. The aim of this study is to investigate the therapeutic effect
of our combination therapy in the ED-B positive F9 teratocarcinoma model, lacking MHCI expression
and known to be dependent on NK immune responses.
Material and methods: In syngeneic F9 tumour bearing 129/FvHsd mice tumour growth delay was
evaluated after local tumour irradiation (10 Gy) combined with systemic administration of L19-IL2.
Immunological responses were investigated using ﬂow cytometry.
Results: Tumour growth delay of L19-IL2 can be further improved by a single dose of RT administered
before immunotherapy, but not during immunotherapy. Furthermore, treatment of L19-IL2 favours a
NK response and lacks cytotoxic T cell tumour inﬁltrating immune cells, which may be explained by
the absence of MHCI expression.
Conclusion: An additive effect can be detected when the NK dependent F9 tumour model is treated with
radiotherapy and L19-IL2 and therefore this combination could be useful in the absence of tumoural
MHCI expression.
 2015 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 116 (2015) 438–442
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Radiotherapy (RT) affects both the tumour and its micro-
environment, leading to the release of tumour-associated antigens,
damage molecular patterns (DAMPs) and the upregulation of
immunomodulatory cell surface molecules, thereby starting an
antitumour immune response [3,4,14]. Recently, we have shown
that the RT induced antitumour effect can be enhanced by admin-
istration of the immunocytokine L19-IL2 [18] which has been
shown to have excellent tumour targeting properties and
improved therapeutic outcome over IL2 treatment alone [8]. The
IL2 moiety of this immunocytokine is able to stimulate the prolif-
eration of cytotoxic T cells and natural killer (NK) cells and can
therefore be used to strengthen a broad RT-induced immuneresponse [2]. The L19 moiety binds to extra domain-B (ED-B), a
part of the ﬁbronectin present in tumour neovasculature and over-
expressed in many solid tumours [11]. RT combined with L19-IL2
has therefore the potential to create powerful synergistic tumour
eliminating effects, as conﬁrmed by our group.
Recently, we reported that the success of this combination
treatment is highly dependent on the presence of cytotoxic T cells
[18]. Cytotoxic T cells are able to recognize and eliminate tumour
cells that express tumour-associated peptides on their MHCI. In
the high ED-B expressing C51 model, these immune cells were
responsible for 75% of tumour cure and in the intermediate ED-B
expressing LLC model an additive effect could be detected.
However, in certain tumours, or in later stages of progression,
tumour cells can downregulate their MHCI expression to escape
from T cell mediated killing. As a consequence, tumour cells
become more prone to be killed by NK cells, since MHCI expression
of tumour cells inhibits the cytotoxic killing of NK cells [10]. As not
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bination of RT with L19-IL2 is also beneﬁcial in these kinds of
tumours. To explore this clinically relevant question, we made
use of the ED-B positive F9 teratocarcinoma model as it is indepen-
dent of T cells and known to induce NK cell responses when treated
with IL2-based therapeutics [2,9]. In this study we investigated
whether the combination of RT with L19-IL2 can provoke a NK cell
mediated immune response in the F9 tumour model and whether
this immune response leads to a therapeutic effect.Material and methods
In vivo experiments
All experiments were performed in accordance with local insti-
tutional guidelines for animal welfare and were approved by the
Animal Ethical Committee of the University of Maastricht.
Approximately 8 week old 129/SvHsd immunocompetent mice
(Harlan Laboratories) were subcutaneously injected with 3106
F9 teratocarcinoma cells resuspended in matrigel (MatrigelTM,
BD Biosciences). F9 cells were cultured in Dulbecco’s Modiﬁed
Eagle Medium (DMEM; Lonza) supplemented with 10% foetal calf
serum in 0.1% gelatin coated dishes. Upon an average tumour vol-
ume of 200 mm3, therapy was started using three different sched-
ules: (I) a single dose of 10 Gy radiotherapy (RT) was locally given
to tumours on day 0, combined with systemic therapy (vehicle
PBS/L19 13.3 lg/IL2 6.7 lg/L19-IL2 20 lg) on day 1, 3 and 5
(Fig. 2A), (II) animals were treated as in I, however sacriﬁced on
day 4 of the treatment schedule and used for ﬂow cytometry anal-
ysis of tumours, spleen and lymph nodes and (III) systemic therapy
was given on day 0, 2 and 4 with local radiotherapy on day 2
(Fig. 3A). For treatment schedule I and III, tumour growth and
treatment toxicity (based on body weight) were monitored on a
daily basis until the tumour volume reached 4 times the volume
at the start of therapy (T4xSV). To calculate T4xSV volumes were
normalized to the start of treatment (day 0). To correctly compare
control groups with radiotherapy groups in treatment schedules I
and III, data were normalized to the start of treatment.Flow cytometry
Flow cytometric analysis was performed on single cell suspen-
sions from tumours, spleen and lymph nodes excised at day 4 as
previously described [18]. Analysis was performed with RBC lysis
buffer (eBioscience, San Diego, CA), FC-block CD16/CD32 (BD
Biosciences) and a combination of antibodies CD3-FITC,
CD4-APC-H7, CD8-PE-CY7, CD19-PE, CD45-V500, CD45-Percp,
CD45-PE, CD45-FITC, CD45-APC, CD45-PE-CY7, CD3e-eFLUO450,
CD4-FITC, CD8a-V500 (BD Biosciences) and NKp46-APC (Miltenyi
Biotec B.V.).Immunoﬂuorescence
7 lm frozen sections were ﬁxed in acetone (4 C) and stained
for ED-B, CD31 and CD8 according to previous published methods
[18] using L19-SIP and KSF-SIP biotinylated (Philochem), rat
anti-CD31 (BD Biosciences) and rabbit anti-CD8 (clone 53.62.7,
Department of Pathology, MUMC, Maastricht, The Netherlands),
respectively. For MHCI staining, sections were blocked with 10%
normal goat serum, incubated overnight at 4 C with primary anti-
body (rat anti-MHCI, 1:50 in antibody diluent, Abcam).
Visualization was done using streptavidin Alexa 488 antibody, goat
anti-rabbit IgG Alexa 488 (Life Technologies), goat anti-rat IgG
Alexa 488 or goat anti-rat IgG Alexa 594 (BD Bioscience).
Fluorescent imaging was performed as described before [18].Statistics
Statistical analyses were performed using GraphPad Prism
Software (v5.03, San Diego, CA). For all parameters medians with
10–90th percentiles are reported. Non-parametric Mann–
Whitney test was used to determine statistical differences.
p-values smaller than 0.05 were considered statistically signiﬁcant.Results
F9 tumours are ED-B positive and MHCI negative
As the immunostimulatory effect of L19-IL2 is dependent on
ED-B expression, we veriﬁed ED-B expression together with the
vascular marker CD31 in the F9 teratocarcinoma model.
Representative sections are shown in Fig. 1A. F9 tumours showed
high ED-B expression associated with CD31 expression. To investi-
gate a possible mechanism underlying RT + L19-IL2 induced NK cell
versus cytotoxic T cell responses, we investigated MHCI expression
of F9 tumours. F9 tumour cells were negative for MHCI expression,
only other structures (i.e. endothelial cells andmouse stromal cells)
stained positive for MHCI. The previously investigated tumour
model C51, which was dependent on cytotoxic T cells [18] was
included as positive control for MHCI staining (Fig. 1B).Combination therapy provides an additive effect
No toxicities were observed based on body weight measure-
ments and animal welfare monitoring. Combination treatment
was performed using two schedules to optimize the best timing
for irradiation when compared with L19-IL2 (Figs. 2A and 3A).
According to the animal welfare regulations, we reduced the
amount of animals by re-using the tumour growth data of single
treatment control groups in schedules I and III.Radiotherapy before immunotherapy
Compared to vehicle PBS treated animals (T4xSV = 3.2 [1.7–4.7]
days), L19 treatment (3.3 [2.5–4.5] days P = 0.9) and IL2 (4.4 [2.5–
5.6] days P = 0.2) treatment alone did not lead to an enhanced
growth delay.
Both RT (4.3 [3.0–8.9] days P < 0.05) and L19-IL2 (7.7 [2.7–13.3]
days P < 0.001) monotherapies signiﬁcantly enhanced tumour
growth delay compared to vehicle. Upon combination of RT with
L19-IL2, a highly signiﬁcant antitumour effect (11.5 [7.9–21.4] days
P < 0.0001) was observed compared to RT + L19 (4.6 [3.0–7.4] days
P < 0.0001) and RT + IL2 (4.7 [3.0–6.9] P < 0.0001) (Fig. 2B).
Flow cytometric analysis demonstrated that the percentage of
baseline NK cells of all lymphocytes (i.e. CD45+ population) in
the tumour was low in vehicle (0.9% [0.3–1.2]) and RT + vehicle
(0.9% [0.5–1.9]) treated animals. This number was signiﬁcantly
increased upon treatment with L19-IL2 (5.4% [2.1–11.5]
P < 0.001) and RT + L19-IL2 (2.7% [1.0–11.7] P < 0.01).
Furthermore, basal levels of CD8 + T cells inside F9 tumours were
low and not increased upon treatment (Fig. 2D).Radiotherapy during immunotherapy schedule
Local irradiation of F9 tumours with 10 Gy (day 2) signiﬁcantly
increased time to reach T4xSV in combination with IL2 (7.1
[5.6–8.9] days) compared to IL2 treatment alone (4.0 [2.7–6.4] days
P < 0.001). However, RT did not show any additional effects on
L19-IL2 treatment (10.1 [7.6–17.7] days) compared to the
immunocytokine treatment alone (8.9 [3.2–14.9] days P = 0.12).
Combining RT with L19-IL2 did signiﬁcantly delay tumour growth
compared to the IL2 combination treatment group (P < 0.001).
Fig. 1. (A) Representative images of ED-B expression in F9 teratocarcinoma. ED-B expression (left) or control (right) in green, vessels (red) and cell nuclei (blue). (B) MHCI
expression (green) and vessels (red) in the F9 teratocarcinoma (left) and MHCI expression in the C51 colon carcinoma (green), cell nuclei in blue. Scale bar represents 100 lm.
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Radiotherapy causes immunogenic death of tumour cells, pro-
motes antigen presentation and alters the tumour microenviron-
ment [16]. Recently, we and others have shown that the selective
delivery of IL2 to the tumour is a promising approach to enhance
the therapeutic potential of RT [15,18]. In this study, we investi-
gated the therapeutic potential and underlying immune response
of the RT and L19-IL2 combination treatment in the ED-B positive
but MHCI negative F9 teratocarinoma tumour model.
Combination of RT with L19-IL2 signiﬁcantly retarded tumour
growth compared to mice treated with RT plus IL2, regardless of
RT timing. RT given before L19-IL2 treatment showed a therapeutic
gain compared to the RT control groups and compared to single
treatment arms. However, RT combined with L19-IL2 did not
retard tumour growth compared with RT plus IL2 treatment group
when the single RT dose was delivered during the immunotherapy
treatment. Therefore the former effective treatment schedule was
used to investigate underlying immunological mechanisms in
more detail. Previously, we described that long-lasting antitumour
effects of RT combined with L19-IL2 are highly dependent on
expression of ED-B and the presence of cytotoxic T cells inside
tumours [18]. In this study, we showed that in the ED-B positive
F9 teratocarcinoma model the number of inﬁltrating NK cells, but
not the number of cytotoxic T cells, are increased upon L19-IL2
treatment compared to vehicle or RT treatment arms. These results
are in agreement with previous publications, where it was shown
that, dependent on the tumour model, the efﬁcacy of targeted IL2
treatment by F16-IL2, F8-IL2, L19-IL2 or NHS-IL2 can be based onNK cells [9,13], T-cells [1,5,15,17], or a combination of both [2,6].
A few possible explanations are available to clarify what favours
an NK or T cell response after treatment with RT + L19-IL2. The
low expression of MHCI may be an important one, since
down-regulation or inactivation of tumour MHCI (which is
involved in antigen processing and presentation) will prevent cyto-
toxic T cells from recognizing and eliminating tumours cells [16].
On the other hand, downregulation of MHC expression on their
surface causes tumour cells to be more vulnerable for NK cell kill-
ing [16], which is in agreement with our recent ﬁndings. However,
in clinical setting, tumours tend to have a heterogeneous expres-
sion of MHCI [7] and therefore a mixture of cytotoxic T cells and
NK cells may become activated when patients are treated with
stereotactic body radiation therapy (SBRT) and L19-IL2 in our clin-
ical study (NCT02086721).
Furthermore, treatment with L19-IL2 alone delays tumour
growth signiﬁcantly, which is in line with previous studies [2],
and was further enhanced by a single dose of 10 Gy applied prior
to L19-IL2 treatment schedule (Fig. 2A) but not by a single dose
of RT given during the immunotherapy treatment schedule
(Fig. 3A). A possible explanation is that the immune response
started after RT can be enhanced by L19-IL2 and therefore RT needs
to be administrated before immunotherapy. Furthermore, RT
might be able to kill inﬁltrating immune cells and therefore RT
administered during the immunotherapy schedule may not have
additional beneﬁt.
However, for the systemic IL2 treatment, we detected a signiﬁ-
cant antitumour immune response when administered before RT
(Fig. 3A). This effect was not detected in the other treatment
Fig. 2. (A) Treatment schedule. (B) Time to reach 4 times start volume (T4xSV) for the different treatment groups (left) and Kaplan–Meier curves showing fraction of tumours
not reaching T4xSV (right). (C and D) Results of ﬂow cytometry analysis, showing the percentage of NKp46+ cells (C) and CD8 + cells (D, right) shows of all CD45+ cells present
in the tumour and representative image of a ﬂuorescent CD8 staining. *P < 0.05, **P < 0.01, ***P < 0.001.
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(Fig. 2A). Similar to our ﬁndings, Milas et al. [12] showed that stim-
ulation of the innate and adaptive immune system (by CpG
oligodeoxynucleotides) prior to a single dose of local RT, is able
to improve the outcome for RT treatment in mouse ﬁbrosarcoma.Interestingly, the ‘radiosensitizing effect’ of systemic IL2 was not
detected when IL2 was administered in the targeted form
(L19-IL2) before RT. Since L19-IL2 binds to ED-B and therefore
stimulates the immune response only locally and since intratu-
moural basal levels of NK cells are very low, systemic IL2 treatment
Fig. 3. (A) Treatment schedule. (B) Scatter-plot showing T4xSV (left) and Kaplan–Meier curves showing the fraction of tumours not reaching T4xSV (right). *P < 0.05,
**P < 0.01, ***P < 0.001.
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tumours to irradiation. Taken together, administration of IL2
before but not after radiotherapy is able to delay tumour growth
in this model and when L19-IL2 is administered before radiother-
apy, this ‘radiosensitizing effect’ is not present.
In conclusion, combination treatment of RT with L19-IL2 is an
efﬁcient treatment combination in the MHCI negative but ED-B
positive F9 tumour model and effects of L19-IL2 can be further
improved by a single dose of RT before immunotherapy treatment.
A single RT dose administered during immunotherapy treatment
seems to be less efﬁcient. Furthermore, the data suggest that treat-
ment of L19-IL2 favours NK and lacks cytotoxic T cell tumour inﬁl-
trating immune cells, which may be explained by the absence of
MHCI expression by these F9 tumours.
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